CXCR4 antagonist plerixafor (AMD3100) combining with anti-PD-1 induced T-cell rapid accumulation among cancer cells and acted synergistically with α-PD-L1 to significantly decrease tumor volume 78. This evidence concerns the gene PDCD1 and neoplasm.